10 Result: Merck
What to Expect: Merck, Gilead Sciences, and Bristol-Myers Squibb Earnings on Deck
April 20th, 2025
Notable companies expected to release their financial results on Thursday, April 24, include: Merck & Co., Inc. (NYSE: MRK), known for its innovative portfolio of prescription medicines and vaccines, will report its first-quarter 2025 earnings bef. Read more
Momentum Builds: Bladder Cancer Trial Data Boost Seagen
September 22nd, 2023
Astellas Pharma Inc. and Seagen Inc. (Nasdaq: SGEN) have reported promising results from the Phase 3 EV-302 clinical trial (KEYNOTE-A39) for PADCEV (enfortumab vedotin-ejfv) combined with Merck & Co., Inc.'s (NYSE: MRK) KEYTRUDA (pembrolizumab) versu. Read more
Breaking Biotech Newsflash: Amgen, Gilead Sciences, and Merck
September 10th, 2023
Amgen Inc. (Nasdaq: AMGN) unveiled encouraging data from the CodeBreaK 101 clinical trial, showcasing the effectiveness of LUMAKRAS (sotorasib) plus chemotherapy (carboplatin and pemetrexed) in treating KRAS G12C-mutated advanced non-small cell lung . Read more
Breaking: Tyson Foods Q3 Misses Mark; Ginkgo Bioworks' Merck Deal Shakes Up
August 07th, 2023
Tyson Foods, Inc. (NYSE: TSN) has released its third-quarter fiscal 2023 financial results, reporting adjusted earnings per share (EPS) of $0.15 and revenues totaling $13.14 billion. These figures fell short of market consensus estimates of $0.26 EPS. Read more
Earnings On The Horizon: Merck, Pfizer, AMD, and Caterpillar - A Preview
July 28th, 2023
Multiple companies are set to report their financial results on Tuesday, August 1, including: Merck & Co., Inc. (NYSE: MRK), a pharmaceutical giant, is expected to announce its second-quarter 2023 earnings results prior to the market opening. . Read more
Momentum: Zura Bio, PDS Biotechnology, THOR Industries Making Pre-Market Moves
June 06th, 2023
Zura Bio Limited (Nasdaq: ZURA) has concluded a private placement that generated approximately $80 million in gross proceeds. This funding milestone enables the company to commence a Phase 2 clinical trial for ZB-106, initially targeting sys. Read more
Promising Clinical Trial Updates and Earnings Reports Drive Stock Price Movements: PDS Biotechnology, eFFECTOR Therapeutics, Costco, and Gap
May 26th, 2023
PDS Biotechnology Corporation (Nasdaq: PDSB) and eFFECTOR Therapeutics, Inc. (Nasdaq: EFTR) shared promising interim data updates from their respective clinical trials, leading to significant stock price movements in after-hours trading. These develo. Read more
Immutep's Eftilagimod Alpha Shows Promise in Phase II Trial, Lightning eMotors Reports Q1 Loss and $50M Pre-Paid Advance Deal, BioNTech Upgraded to Buy
May 17th, 2023
Immutep Limited (Nasdaq: IMMP) has received positive feedback from the US Food and Drug Administration (FDA) for its late-stage clinical development plans for Eftilagimod Alpha ("efti") in the treatment of 1st line non-small cell lung cancer. In addi. Read more
Lucintel Forecasts Epigenetic Market to grow at a CAGR of 14% from 2019 to 2024
December 08th, 2021
Dallas, TX / CRWE PRESS RELEASE / Dec. 9, 2021 - According to the recent study the Epigenetic Market is projected to grow at a CAGR of 14% from 2019 to 2024. Growth in this market is primarily driven by declining sequencing costs and time, incre. Read more
Lucintel Forecasts Primary Cell Market to Grow at a CAGR of 7%-9%
September 12th, 2021
Dallas, TX / CRWE PRESS RELEASE / Sep. 12, 2021 - According to the recent study the primary cell market is projected to grow at a CAGR of 7%-9% from 2020 to 2025. Growth in this market is primarily driven by increasing cancer research and rapid. Read more
Want To Find Some News?
News By Industries
Recent Post
-
Key Earnings Ahead for Netflix, Fastenal, and U.S. Bancorp
January 18th, 2026Louisville Thunder Appoints Veteran Coach Mike Reed to Lead Program
January 15th, 2026FDA Approves First Treatment for Children With Menkes Disease
January 13th, 2026January 13th, 2026Wall Street Eyes Bank of America, Wells Fargo, Citi Ahead of Earnings
January 11th, 2026
Member Login